ArticleDiscover oncology2025
The value of dual-energy CT radiomics in evaluating vascular maturity and prognosis in clear cell renal cell carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeThis study aims to develop an integrated model based on dual-energy CT (DECT) radiomic features to predict vascular maturity and progression-free survival (PFS) in patients with clear cell renal cell carcinoma (ccRCC).
methodsA total of 87 ccRCC patients who underwent resection were randomly divided into training (n = 60) and validation (n = 27) groups at a 7:3 ratio. Radiomics models (single/multi-energy sequences), a clinical model, and a combined model were developed to predict vascular maturity (CD34+/α-SMA+ cells). Additionally, 17 patients were recruited from Center II as an external validation cohort for the multi-energy sequence models. A nomogram combining the radiomic score (Rad-score) and clinical features was constructed to visually predict patients’ PFS. Kaplan-Meier survival analysis assessed PFS differences between high and low CD34+/α-SMA+ cell groups.
resultsThe median values of CD34+/α-SMA+ cells served as the cutoff for vascular maturity classification. The combined model demonstrated excellent performance, achieving an AUC of 0.967 in the validation set and 0.764 in the external validation set. Among the radiomics models, the multi-energy sequences model performed best, with an AUC of 0.833 in the validation set and 0.736 in the external validation set. Kaplan-Meier survival analysis revealed statistically significant PFS differences between CD34+/α-SMA+ cell groups.
conclusionsThe combined model integrating Rad-score and clinical features showed promising predictive ability for assessing vascular maturity and PFS between CD34+/α-SMA+ groups in patients with ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.